Wedbush Securities is making a big statement on Tesla (NASDAQ:TSLA), naming it to its Best Ideas List even though the stock has had a rough start to the year. According to analyst Dan Ives, Tesla ...

Wedbush analysts called Palantir one of their "top names" to own in 2025 despite recent losses. Shares of Palantir have lost one-third of their value in the wake of a report last month that the ...

LOS ANGELES, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Wedbush, a Los Angeles-based financial services firm with global reach, and a legacy of innovation and client-focused investment solutions ...

Investing.com-- Analysts at Wedbush Securities have added Tesla Inc (NASDAQ:TSLA) to their "Best Ideas List", citing expectations for a major innovation cycle ahead. Wedbush maintained an ...

Wedbush made a splash on Tuesday with the announcement that it was entering the ever-growing exchange-traded fund market. With more than 7K ETFs listed globally, collectively managing over $10T in ...

However, Wedbush’s team said Musk has a good track record of balancing multiple initiatives and accelerating innovation at Tesla. Put simply, Wedbush views these as containable brand issues that ...

LOS ANGELES, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Wedbush, a Los Angeles-based financial services firm with global reach, and a legacy of innovation and client-focused investment solutions, introduces ...

Wedbush has a “Outperform” rating and a $90.00 price objective on the stock. The consensus estimate for Apogee Therapeutics’ current full-year earnings is ($3.09) per share.

iTeos Therapeutics (NASDAQ:ITOS – Get Free Report)‘s stock had its “outperform” rating restated by investment analysts at Wedbush in a research report issued on Wednesday,RTT News reports.

Welltower (NYSE:WELL) was upgraded at Wedbush after the senior housing REIT "impressed with the growth outlook for 2025". The healthcare REIT turned in Q4 earnings and revenue that topped Wall ...

Wedbush analyst Henry Coffey maintained a Hold rating on UWM Holding (UWMC – Research Report) today and set a price target of $6.50. The company’s shares closed last Friday at $6.28. See what ...